Helus Pharma, operating under Cybin (HELP), reported that enrollment in its APPROACH Phase 3 trial of HLP003 for major depressive disorder (MDD) is progressing as…
June 23, 2026
Quoin Pharmaceuticals Secures FDA Conditional Approval of QYLEKI™ Brand Name for QRX003
Another step in preparing QRX003 for potential commercialization Quoin Pharmaceuticals (NASDAQ: QNRX) has received FDA conditional approval of QYLEKI™ as the proposed brand name for…
June 22, 2026
BridgeBio’s Oral Infigratinib Shows Strong Phase 3 Growth Data in Children With Achondroplasia
BridgeBio Pharma Inc. (NASDAQ: BBIO) announced Phase 3 data for its oral achondroplasia therapy infigratinib from the PROPEL 3 trial at ICCBH 2026, putting a…
Parabilis Medicines’ (NASDAQ: PBLS) Wall Street debut just reset the bar for biotech IPOs, with the cancer‑focused peptide company raising 670 million dollars in an…
June 10, 2026
Lexaria Advances Next-Generation GLP-1 Research With Completion of Dosing in New Animal Study
Lexaria Bioscience Corp. (NASDAQ: LEXX) has completed dosing in its 2026 Animal Study #2 (GLP-1-A26-2), which is evaluating orally delivered formulations of two next-generation GLP-1…
RedHill Biopharma’s (NASDAQ: RDHL) oral drug candidate opaganib has received Rare Pediatric Disease (RPD) designation from the U.S. Food and Drug Administration for the treatment…
Biogen Inc., (NASDAQ: BIIB) is quietly strengthening its rare‑disease pipeline, with its investigational spinal muscular atrophy (SMA) therapy salanersen earning a coveted Breakthrough Therapy designation…
TG Therapeutics (NASDAQ: TGTX) is trading higher after fresh clinical data supported a more convenient, under‑the‑skin version of its multiple sclerosis therapy Briumvi (ublituximab‑xiiy), reinforcing…
Eli Lilly and Company (NYSE: LLY) announced that its targeted therapy Retevmo (selpercatinib) cut the risk of disease recurrence or death by 83 percent versus placebo in patients with…
Johnson & Johnson (NYSE: JNJ) has received FDA approval for a label expansion for TREMFYA (guselkumab), confirming it as the only IL‑23 inhibitor proven to…
BridgeBio Pharma (NASDAQ: BBIO) has received FDA acceptance and Priority Review for its investigational therapy BBP-418, which could become the first-ever approved treatment for limb-girdle…
GoodRx Inc. (NASDAQ: GDRX) has launched GoodRx Companion, a $14.99 per month subscription designed to lower everyday healthcare costs for people who are uninsured, underinsured, or…